Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kazakhstan cancer study to reveal Real-World treatment patterns

NCT ID NCT07593196

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will review medical records of about 240 adults in Kazakhstan with HER2-positive metastatic breast cancer to see how they were treated and how well they did. Researchers will look at treatments given in routine care (except one specific drug) and track outcomes like how long the cancer stayed controlled. The goal is to understand real-world practices and patient characteristics, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This non-interventional multicenter observational study will include 240 adult patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan). Patients will be included in about 12 oncological centers (in each center it is expected to recruit about 20 patients) in various regions of Russian Federation

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with HER2-positive mBC who are receiving or have started any anti-HER2 therapy (except for trastuzumab deruxtecan) at the time of inclusion * The diagnosis of mBC was established between the 1st January 2022 to 31st December 2023 * Patients with the availability of at least 24 months of follow-up data (from the date of mBC diagnosis) in the medical records at the participating site, unless patient died/moved or refused the therapy within the first 24 months of diagnosis * Age ≥18 years at the time of inclusion Exclusion Criteria: * Presence of other malignancies within the period from mBC diagnosis until the timepoint of data collection * Patients received trastuzumab deruxtecan * The participation in any interventional trial within period since diagnosis until the end of study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-positive metastatic breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 'Centre for Nuclear Medicine and Oncology' Abai Regional Health Authority Semey

    Semey, 71407, Kazakhstan

  • 'General Regional Hospital' of the municipal state institution 'Health Department of the Akimat of North Kazakhstan Region' Petropavlovsk

    Petropavl, 150000, Kazakhstan

  • 'Karaganda General Hospital No. 3' of the Karaganda Region Health Department

    Karaganda, 100019, Kazakhstan

  • 'Kazakh Research Institute of Oncology and Radiology (KAZNIOR)'

    Almaty, 50022, Kazakhstan

  • 'Multidisciplinary Medical Centre' of the Astana City Administration

    Astana, 10000, Kazakhstan

  • 'Regional Cancer Centre' Uralsk

    Oral, Kazakhstan, 90005, Kazakhstan

  • 'Regional Clinical Hospital' of the Health Department of the Turkestan Region

    Shymkent, 160011, Kazakhstan

  • 'Shymkent City General Hospital with Oncology Centre' under the Shymkent City Health Department

    Shymkent, 160000, Kazakhstan

  • 'The Zhambyl Regional Multidisciplinary Centre for Oncology and Surgery' of the Health Department of the Zhambyl Regional Administration, Taraz

    Taraz, 80000, Kazakhstan

  • Almaty Cancer Centre

    Almaty, 50054, Kazakhstan

  • Medical Centre of the Marat Ospanov West Kazakhstan Medical University, Aktobe

    Aktobe, 30017, Kazakhstan

  • National Cancer Research Centre, Astana

    Astana, 10017, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.